Skip to content

Study · Non-randomized trial · n = 272 · 2014

4 results

[Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke].

Aliferova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MIu, Meshkova KS, Salimov KA, Stakhovskaia LV, Chefranova ZhIu, Shamalov NA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2014Cited by 2 (Europe PMC)

PMID24874316 (opens in a new tab)PepBankPUB-24874316
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, cortexin had high reported clinical efficacy.

    In plain wordsIn patients with ischemic stroke, cortexin had high reported treatment efficacy.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedOverall clinical efficacy
    Study

    n = 272

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mg three times a day · intramuscularAs given in this study (human).

    Source sentences

    Summary
    High efficacy and safety of cortexin in the complex treatment of patients with II has been shown.
    3 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled trial has been carried out.
    Summary · context
    Two hundreds and seventy-two patients with II have been enrolled in the trial.
    Summary · context
    Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with ischemic stroke, cortexin had high reported safety without event details.

    In plain wordsIn patients with ischemic stroke, the study reported high safety for cortexin but gave no event details.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedOverall safety
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg three times a day · intramuscularAs given in this study (human).

    Source sentences

    Summary
    High efficacy and safety of cortexin in the complex treatment of patients with II has been shown.
    3 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled trial has been carried out.
    Summary · context
    Two hundreds and seventy-two patients with II have been enrolled in the trial.
    Summary · context
    Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, two cortexin courses had the best therapeutic effect compared with one course followed by placebo.

    In plain wordsAfter ischemic stroke, two cortexin courses had better treatment effects than one course followed by placebo.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseTherapeutic effect of repeated courses
    Study

    n: not reported in source

    Comparator
    One cortexin course followed by placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mg three times a day · intramuscular · Two 10-day coursesAs given in this study (human).

    Source sentences

    Summary
    The best therapeutic effect was seen in group 1 (two 10-day courses of cortexin).
    3 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled trial has been carried out.
    Summary · context
    Two hundreds and seventy-two patients with II have been enrolled in the trial.
    Summary · context
    Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, two cortexin courses had the best therapeutic effect compared with two placebo courses.

    In plain wordsAfter ischemic stroke, two cortexin courses had better treatment effects than two placebo courses.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseTherapeutic effect of repeated courses
    Study

    n: not reported in source

    Comparator
    Two placebo courses
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mg three times a day · intramuscular · Two 10-day coursesAs given in this study (human).

    Source sentences

    Summary
    The best therapeutic effect was seen in group 1 (two 10-day courses of cortexin).
    3 context sentences
    Summary · context
    A multicenter prospective double-blind placebo-controlled trial has been carried out.
    Summary · context
    Two hundreds and seventy-two patients with II have been enrolled in the trial.
    Summary · context
    Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.